News | August 30, 2011

PCI Offers Optimal MI Reperfusion; Not Accessible in All Areas of Europe

August 30, 2011 – Primary percutaneous coronary intervention (PCI) is the best reperfusion therapy for patients presenting with acute ST-elevation myocardial infarction. Researchers used the Western Denmark Heart Registry to describe the implementation of primary PCI in Denmark. Their study (including almost 10,000 patients) showed that a strategy with early diagnosis, based on electrocardiogram (ECG) recording in the ambulance and directing the patients straight to the catheterization laboratory in the primary PCI center, was associated with a lower mortality. The data was presented this week at the annual meeting of the European Society of Cardiology (ESC) in Paris.

Direct access to PPCI is unfortunately still not possible in many European countries. A survey from 2007/8 showed that only 40 percent of European patients with ST-elevation myocardial infarction are treated with primary PCI.

The Stent for Life (SFL) Initiative launched by the ESC, the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and EuroPCR (the official congress of the EAPCI) is aiming to support the implementation of primary PCI in the ESC countries. Selected target countries are Bulgaria, Egypt, France, Greece, Italy, Portugal, Romania, Serbia, Spain and Turkey.

The barriers for implementation are a complex mix of medical, organizational, patient-related, regulatory and economic factors, and differ from country to country. Therefore, the action plan for implementation is tailored to the specific needs of each country and is managed at country level by the country SFL Initiative and supported by national cardiology societies. Preliminary data from several countries show an increase in the numbers of primary PCIs performed after the SFL action plan was launched. More detailed information about changes in availability of primary PCI in Europe will be available next year where the result of the ongoing 2011 survey will be presented.

The activities at the national level are undertaken in close collaboration with the Emergency Medical Service and transportation protocol, and campaigns are worked out to decrease treatment delay. System delay can be decreased by an effective pre-hospital diagnosis and triage.

Reduction of patient delay in contacting services is another main target. An important strategy for the Stent for Life Initiative is to launch public awareness campaigns about acute coronary syndrome (ACS) symptoms in order to encourage patients to call the Emergency Medical Services directly in the event of an acute onset of chest pain.

For more information: www.escardio.org


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now